Skip to main content

Endocrine and metabolic complications in children and adolescents with Sickle Cell Disease: an Italian cohort study



Children with Sickle Cell Disease (SCD) show endocrine complications and metabolic alterations. The physiopathology of these conditions is not completely understood: iron overload due to chronic transfusions, ischemic damage, and inflammatory state related to vaso-occlusive crises may be involved. Aims of this study were to evaluate the growth pattern, endocrine complications, and metabolic alterations and to detect the relationship between these conditions and the SCD severity in affected children and adolescents.


Fifty-two children and adolescents with SCD [38 homozygous sickle hemoglobin (HbSS) and 14 heterozygous sickle hemoglobin (HbSC); age range 3–18 years] were recruited. Anthropometric [height, body mass index (BMI), arm span, sitting height, target height (TH), and pubertal status] and laboratory [blood cell counts, hemolysis indices, metabolic and nutritional status indices and hormonal blood levels] data were evaluated. The SCD severity was defined according to hematological and clinical parameters.


Height-SDS adjusted for TH and BMI-SDS were significantly higher in HbSC children than in HbSS ones. Forty-eight out of 52 patients (92%) had at least one metabolic and/or endocrine alteration: insufficiency/deficiency of vitamin D (84.7%), insulin resistance (11.5%), growth hormone deficiency (3.8%), subclinical hypothyroidism (3.8%), and hypogonadism (1.9%). Levels of vitamin D were significantly and negatively correlated with clinical indicators of the SCD severity. Subjects with HbSS genotype show significant lower levels of both insulin-like growth factor-1 (IGF-1) and insulin-like growth factor binding protein 3 than children with HbSC. In the study population IGF-1 values were significantly and positively correlated with Hb and negatively with lactate dehydrogenase.


Metabolic alterations and endocrine complications are very common in children and adolescents with SCD. A regular follow-up is necessary to identify subjects at risk for complications to precociously start an appropriate treatment and to improve the quality of life of SCD patients.

Peer Review reports


Sickle cell disease (SCD) is an inherited disease due to a single-point mutation on the β-globin subunit of hemoglobin (Hb) determining polymerization of the mutant HbS and resulting in sickling of erythrocytes. It is characterized by a high clinical variability because of inflammation, hemolysis, and micro-vascular obstruction leading to unpredictable acute complications and chronic organ damage [1, 2]. The HbS mutation can be inherited in homozygosis (HbSS) or in heterozygosis with other β-globin qualitative (HbSC) or quantitative (HbSβ0 and HbSβ+) defects. Subjects affected by HbSS and HbSβ0 have the most severe phenotype while the other forms have milder clinical manifestations [3].

In high-income countries the great and continuous rise of the SCD survival rate demonstrated in the last decades was mainly due to newborn screening programs [4,5,6], advances in the supportive care, and a better use of disease modifying agents such as Hydrxyurea (HU) [7]. However, the reduction of mortality has led to an increase of long-term complications, including also metabolic and endocrine ones.

Specifically, poor growth and delay of pubertal development are the most frequent disorders observed in children and adolescent with SCD. Children with SCD have lower height, weight, and body mass index (BMI) than healthy controls [8]. However, published data on endocrine and metabolic disorders during childhood and adolescence, such as gonadal insufficiency, thyroid dysfunction, and bone and glycemic metabolism, are really few [9,10,11]. The pathophysiology of these complications is not yet fully understood. Endocrine disorders appear to be related to vaso-occlusive and ischemic events, rather than iron overload resulting from frequent transfusion [9]. According to the literature, the prevalence of endocrine and metabolic disorders in children with SCD varies in different populations depending on the literacy rate, socioeconomic status, and access to appropriate treatment [7, 9, 10, 12]. In children with HbSS, the treatment with HU has been demonstrated to allow growth rates similar to patients with HbSβ+ or healthy controls [13].

Aims of the present study were to define the growth pattern, endocrine complications, and metabolic alterations in children and adolescents with SCD and to evaluate the role of therapeutic regimens in improving anthropometric, endocrine, and metabolic parameters.


Study design and setting

This was a cross-sectional population study. We evaluated 52 children and adolescents with SCD (38 with HbSS and 14 with HbSC) at steady state, aged between 3 and 18 years, who were recruited during the first six months of 2017.

Patients with acute complications or comorbidities (genetic disease, congenital heart disease, neurological disease), lost to follow-up or transferred to other centers were excluded.

The study was approved by the Ethics Committee of the University of Modena and Reggio Emilia (Protocol number 213/16). Written informed consent was obtained from all parents at the moment of recruitment in the study and before the first data collection. The study database was created before the beginning of patient’s recruitment and was approved by the local EC before data collection.

Data collection

Anthropometric parameters [height, weight, body mass index (BMI), arm span, sitting height] were evaluated in all recruited subjects. Height and sitting height were measured to the nearest 0.1-cm with a wall-mounted stadiometer and stadiometer for sitting height (Harpenden, Crymych; UK), respectively. Body weight was measured to the nearest 0.1-kg. Arm span was represented by the distance, measured in cm, between the end of the third finger of the two hands and it was measured to the nearest 0.1-cm with a no extensible meter. We calculated: sitting height/height ratio, arm span/height ratio, and BMI (weight in kg/height in meters squared).

Height-SDS and BMI-SDS were reported according to age- and sex- specific World Health Organization (WHO) growth chart 2007 [14]. Parental height was also collected to estimate target height (TH) according to the formula: [(mother’s height + 13) + father’s height]/2 in males and [(mother’s height - 13) + father’s height]/2 in females [15]. In all the participants pubertal development was determined using the grading system defined by Tanner for breast (B) and genital stage (G) according to gender [16].

Blood and plasma samples were collected in all SCD children to measure: blood cell counts [red blood cells, white blood cells (WBC), neutrophils (N), hemoglobin (Hb), platelets (PTL)], lactate dehydrogenase (LDH) as hemolysis index, iron levels, metabolic and nutritional status indices [fasting glucose (enzymatic test Gluco-Quant, Roche), fasting insulin (chemiluminescent immunometric assay, Immunolite 2000, Siemens healthcare), lipid status [total cholesterol, high-density lipoprotein (HDL-C), low-density lipoprotein, tryglicerides) (enzymatic test Hitachi, Roche Diagnostic)], thyroid hormones [thyroid-stimulating hormone (TSH) and free thyroxine 4 (fT4) (fluorometric assay AutoDELFIA automatic immune assay system)], vitamin D (chemiluminescent immunometric assay, BAYER, Germany), reproductive and growth function [luteinizing hormone (LH), follicle stimulating hormone (FSH), prolactin, estradiol, testosterone, insulin-like growth factor-1 (IGF-1), (chemiluminescent immunometric assay, BAYER, Germany), and insulin-like growth factor binding protein-3 (IGFBP-3) (ELISA test)].

Vitamin D insufficiency and deficiency were defined by 25-hydroxy-vitamin D levels between 10 and 30 ng/ml and < 10 ng/ml, respectively.

Insulin resistance was estimated using the homeostasis model assessment (HOMA) model as fasting insulin (microU/L) x fasting glucose (mmol/L)/22.5. Insulin resistance was defined by HOMA-IR values of ≥3.16 in pubertal subjects and HOMA-IR of ≥2.67 in prepubertal ones [17, 18].

Subclinical hypothyroidism was defined by normal FT4 values associated to TSH > 5 μIU/ml [19].

Growth hormone (GH) deficiency (GHD) was diagnosed according to both specific anthropometric (height < − 3 SDS or height < − 2 SDS associated with height growth velocity < -1SDS) and biochemical parameters (GH peak values < 10 ng/ml in 2 different pharmacologic stimulation tests) [20].

Hypergonadotropinic hypogonadism was defined by high serum gonadotropin concentrations in the absence of pubertal signs at the appropriate age for puberty [21].

Ovarian insufficiency was defined in post pubertal female with secondary amenorrhea, high concentration of FSH and low anti-mullerian hormone (AMH) levels [21].

The severity of SCD was evaluated according to the following indices: the average of total Hb and LDH (year 2016), the average number of hospitalizations and days of hospitalization (year 2016), the average number of hospitalizations of the last five years, and the total number of lifetime Acute Chest Syndrome (ACS) episodes.

Statistical analysis

Descriptive data are reported as mean ± standard deviation (SD), number of observations, and percentages. Data were checked for normal distribution using the Kolmogorov-Smirnov test, so non-parametric statistical analysis (STATISTICA™ software, StatSoft Inc., Tulsa, OK, USA) was performed.

Subjects’ data were analyzed according to gender (males vs. females), SCD genotype (HbSC vs. HbSS), HDL-C levels (cut-off 40 mg/dl), and HU treatment (HU > 1 year vs. HU < 1 year).

Between-group comparisons were performed using the Mann-Whitney U-test. Spearman correlation was used to evaluate correlations between clinical, anthropometric, and biochemical parameters.

For each test, statistical significance was considered for p < 0.05.


This study reports data from 52 children and adolescents (29 males, 55.7%) with SCD having mean age of 11.1 ± 4.6 years. Thirty-eight subjects (73%) presented HbSS genotype while others were HbSC. Among our population, 50% of patients was pubertal; 9 out of 23 female had menarche (average age of menarche 12.8 years). Analyzing patients according to the genotype (HbSS and HbSC), 42% of subjects with HbSS and 70% of subjects with HbSC were pubertal.

HbSS showed lower level of Hb and higher level of HbS %, WBC, PTL, LDH, and bilirubin than HbSC ones (Table 1).

Table 1 Laboratory data in HbSS patients vs. HbSC patients

Anthropometric parameters

Subjects with HbSC genotype compared to HbSS ones showed significantly higher values of both height-SDS adjusted for TH (1.0 ± 0.6 vs. 0.3 ± 0.9 SDS, respectively; p = 0.027) and BMI-SDS (0.9 ± 1.1 vs. -0.7 ± 1.4 SDS, respectively; p = 0.004) despite chronological age was not different (Table 2; Fig. 1). Analyzing data according to gender no difference was found in anthropometric parameters (Additional file 1: Table S1).

Table 2 Anthropometric parameters in HbSS patients vs. HbSC patients
Fig. 1

Anthropometric parameters according to SCD genotype. BMI-SDS in HbSC group was significantly higher than in HbSS group (p = 0.004). Height-SDS adjusted for TH in HbSC group was significantly higher than in HbSS group (p = 0.027)

Height-SDS adjusted for TH was significantly and negatively correlated with clinical severity parameters such as number of hospital admissions/2016 (Spearman R = − 0.31 p = 0.040), average number of days of hospital admissions/2016 (Spearman R = − 0.31, p = 0.041), and average number of ACS (Spearman R = − 0.40, p = 0.008).

Two out of 52 of SCD subjects (3.8%) showed height-SDS < − 2 SDS and 9.6% (5/52) showed BMI-SDS < − 2 SDS. Patients on treatment with HU for more than one year (29/52, 56%) respect to those on HU for less time had lower values of BMI-SDS ​​ (− 0.8 ± 1.4 vs. 0.4 ± 1.2 SDS, respectively; p = 0.008) and sitting height/height ratio (0.50 ± 0.02 vs. 0.52 ± 0.02, respectively; p = 0.004) (Fig. 2).

Fig. 2

Anthropometric parameters according to HU therapy groups. Patients in HU > 1-year group, respect to HU < 1-year one, had both significantly lower BMI-SDS (p = 0.008) and sitting height/height ratio (p = 0.004)

Prevalence of metabolic and endocrine complications

The prevalence of metabolic alterations and endocrine complications among SCDs was high: 48 out of 52 patients show at least one metabolic and/or endocrine alteration. Among all patients, 41 (79%), 6 (11.5%), and 1 (1.9%) presented respectively one, two, and three alterations at the same time. The most detected conditions were the vitamin D insufficiency/deficiency (84.7%), the insulin resistance (11.5%), and to a lesser extent the GHD (3.8%), the subclinical hypothyroidism (3.8%), and the hypergonadotropic hypogonadism (1.9%) (Table 3).

Table 3 Prevalence of endocrine and metabolic alterations in children and adolescents with SCD

Vitamin D insufficiency/deficiency

In particular, in 63.5% of patients vitamin D levels were between 10 and 30 ng/ml while in 21.2% were < 10 ng/ml. We found a significant negative relationship between plasmatic levels of vitamin D and clinical severity of the disease, represented by number of hospital admissions/2016 (Spearman R = − 0.29 p = 0.040), average number of days of hospital admissions/2016 (Spearman R = − 0.29, p = 0.034) and average number of hospital admissions in the last 5 years (Spearman R = − 0.36, p = 0.009).

Glucose and lipid metabolism

Analyzing data according to HDL-C levels, we found that subjects with HDL-C > 40 mg/dl, respect to those with HDL-C < 40 mg/dl, had significantly higher levels of vitamin D (22.4 ± 11.2 vs. 18.2 ± 17.3 ng/ml, respectively; p = 0.044). The mean values of HDL-C were correlated with neutrophils (Spearman R = − 0.29, p = 0.041), LDH (Spearman R = − 0.29, p = 0.037), and serum ferritin (Spearman R = − 0.40, p = 0.003) (Fig. 3).

Fig. 3

Relationship between HDL-C values and parameters of clinical severity

The 11.5% of subjects had insulin resistance as suggested by abnormal HOMA-IR values. However, HOMA-IR was not different between HbSS and HbSC subjects.

Growth and gonadotropin

GHD was detected in 2 boys (3.8%) with HbSS genotype, who have been started human recombinant GH replacement therapy.

In addition, patients with HbSS genotype compared to HbSC ones showed lower levels of IGF-1 (211.7 ± 93.2 vs. 315.3 ± 89.3 ng/ml, respectively; p < 0.001) and IGFBP-3 (3267.1 ± 828, 4 vs. 3761.7 ± 773.5 ng/ml, respectively; p < 0.001) (Fig. 4). IGF-1 values were significantly correlated with both Hb (Spearman R = 0.51, p = 0.0001) and LDH levels (Spearman R = − 0.44, p = 0.0009) (Fig. 5).

Fig. 4

IGF-1 and IGFBP-3 values according to SCD genotype. In HbSC group both IGF-1 and IGFBP-3 levels were significantly higher respect to HbSS group (p < 0.0001)

Fig. 5

Relationship between values of IGF-1 and parameters of clinical severity

Ovarian insufficiency was detected in one 17-years old girl with normal secondary sexual characteristics for age, with secondary amenorrhea, high concentration of FSH and low levels of AMH.

Diagnosis of hypergonadotropic hypogonadism was also performed in a 15-years old male with HbSS genotype and with Tanner Stage 1 (testes 3 ml bilateral).

The mean values ​​of testosterone in our males were also positively correlated with the mean values ​​of Hb (Spearman R = 0.40, p = 0.029). No correlation between IGF-1, IGFBP-3, TSH, fT4, testosterone, estradiol, LH, FSH levels and ferritin values [both as a relative value at the time of enrollment and as the average value of the last two years (2015–2017)] were identified in our population both in prepubertal and in pubertal patients.


Survival rate among children with SCD has increased especially in the recent decades, due to an earlier diagnosis and a better quality of care. Consequently, the incidence of long-term complications, such as metabolic and endocrine disorders, is increasing in SCD population and it has become a main concern to treat them properly, improving their prognosis and their quality of life. In this study we demonstrated a high prevalence (92%) of endocrine complications and metabolic alterations in the pediatric SCD population, mainly represented by vitamin D insufficiency or deficiency, insulin resistance, and to a lesser extent GHD, subclinical hypothyroidism, and hypogonadism. In literature, it is really difficult to understand the cumulative incidence of these disorders in subjects with SCD because of published studies evaluated mainly one single endocrine alteration. Specifically, growth impairment and delayed puberty are the most frequent disorders observed among SCD pediatric patients [10, 11].

Özen et al. reported that 50% of the examined population show endocrine disorders mainly represented, as in our study, by insufficiency/deficiency of vitamin D and to a lesser degree of osteopenia, hypoplasia/testicular atrophy, hypogonadism, hypothyroidism, and insulin resistance [22].

In our study the prevalence of endocrine complications was even higher that those reported by Özen et al. [22], but it is important to consider that the majority of our subjects were immigrants, coming mainly from Africa (96%) with socio-economic conditions that may influence the anthropometric, endocrine and metabolic parameters.

It has been demonstrated that children with SCD had a poorer growth compared to matched healthy subjects [23]. Near two thirds of SCD patients experience a decline in one or more growth parameters (height, weight, and BMI) and the incidence of growth retardation (defined by the presence of one or more of anthropometric parameters below the 5th percentile) could reach the 38% during the follow-up [24]. In our population, the prevalence of growth alterations was about 3.8% when height was considered <-2DS ​​and 9.6% when BMI-SDS was considered <-2SD. The discrepancy between our results and previous published data [24] could be explained by differences in the study design (longitudinal vs. transversal study).

The underline mechanism on growth delay in SCD is very complex and probably influenced by many variables, such as hematologic and cardiovascular status, socio-economic factors, endocrine function, metabolic function and nutritional status [25].

It has been shown that the mean height SDS of children with SCD is comparable to those of children with constitutional growth delay but it is higher than those of children with GHD [26, 27]. In agreement with published data, our study demonstrated that growth was more affected in subjects with HbSS genotype than in subjects with HbSC genotype.

According to the therapeutic regimen, significant differences were found with respect to BMI-SDS and sitting height/height ratio. Although not expected, patients treated with HU for more than one year had lower BMI-SDS and sitting height/height ratio. The reason of these findings is likely related to the more severe phenotype of patients treated with HU for more than a year. In fact, in our opinion, the disease severity could influence these anthropometric parameters. However, it would be important to continue these evaluations in order to assess whether treated patients may have an improvement in growth parameters over time by a reduction in clinical severity. In fact, the prospective use of HU can both improve clinical outcome of the disease and also positively influence growth and development, reducing the risk of iron overload due to the chronic transfusion regimen.

Our data showed significant correlations between clinical parameters of disease severity and anthropometric parameters: children with better control of the disease (expressed as lower number of hospital admissions in 2016, lower number of days of hospitalization in 2016 and lower ACS) had higher values of height-SDS adjusted for TH. Subjects with HbSS genotype showed a negative correlation between the number of ACS and the values of height-SDS adjusted for TH. A good clinical control of the disease seems not only to affect the survival but also to reduce the long-term comorbidity.

In our SCD population, vitamin D insufficiency was demonstrated in 63.5% while 21.2% had a deficient level. In a study conducted by Buison et al., 65% of children with SCD had levels of vitamin D lower than those of healthy children [28]. Jackson et al [29] reported that 96% of SCD patients had vitamin D level between 10 and 20 ng/ml. Severe vitamin D deficiency (< 10 ng/ml) was found in 64% of subjects and it was demonstrated to be associated with age and reduction in lung function but not with pain and/or ACS episodes. In a Spanish study on vitamin D status in 78 children with SCD, Garrido et al. [30] report that near to 80% and 56.4% had vitamin D level < 30 ng/ml and < 20 ng/ml, respectively.

The vitamin D metabolism is complex because of the involvement of different organ including skin, intestines, liver, kidney, and parathyroid [9]. Patients with SCD have some peculiar characteristics that can lead to the development of vitamin D deficiency such as decreased appetite or reduction of nutrients absorption due to the intestinal mucosa damage. Continuous red blood cells production to compensate anemia characterize SCD and causes an increase of basal metabolic rate with higher nutritional demands [8, 31]. Moreover, in SCD patients with renal impairment conversion of vitamin D to its active form can be reduced. Finally, vitamin D binding protein levels can be low being SCD an inflammatory disease [28]. The importance of vitamin D assessment in patients with SCD is supported by the demonstration that vitamin D deficiency is more frequent among children with SCD than in controls [32].

The different prevalence of vitamin D deficiency/insufficiency demonstrated between African Americans and Caucasians populations can be explained by the decreased synthesis of vitamin D in the skin [33] and differences in dietary habits [34]. A better absorption of dietary calcium and lower levels of vitamin D binding protein have been demonstrated in African Americans subjects compared to Caucasians [35, 36]. This suggests that neither the optimal Vitamin D threshold for Caucasians nor levels suggested for healthy African Americans are applicable to patients with SCD [32]. It is therefore really important to identify the optimal level of vitamin D in children and adults with SCD, in particular in patients of African origin living in European Countries, as patients enrolled in our study.

In our population, vitamin D levels showed an inverse and statistically significant correlation with the number of admissions and hospitalizations in 2016 and the average number of admissions in the last 5 years, suggesting that this deficit could adversely affects the clinical severity of the disease.

It was hypothesized that inadequate levels of vitamin D could be linked to a condition of chronic inflammation, as well as low levels of HDL-C [37]. This finding is confirmed also in our population study. Dividing our patients into two groups according to HDL-C levels, we found that vitamin D values ​​were significantly lower in the group of patients with lower HDL-C values (< 40 mg/dl). In addition, HDL-C values ​​of our population showed a negative relationship (p < 0.05) to neutrophils percentage, LDH and ferritin values, particularly in subjects with HbSS genotype. Seixas et al. [37] found a negative association between LDH and HDL-C levels, showing how low HDL-C levels could be a prognostic marker of hemolysis and endothelial dysfunction in view of their anti-inflammatory, anti-oxidant, anti-aggregating, anti-coagulant and pro-fibrinolytic role. Patients with SCD and high HDL-C levels had fewer reticulocytes, WBC, monocytes, PTL, and erythroblasts and a lower concentration of HbS as well as a lower concentration of hemolytic markers. Our data confirm that HDL-C and vitamin D could play an important role in inflammatory condition such as SCD.

The 3.8% of our population showed GHD. An impairment of the GH-IGF1-IGFBP3 axis was demonstrated in SCD subjects [38, 39]. Children with SCD have significantly decreased IGF-1 concentrations compared to children with constitutional delay of growth. The poor synthesis of IGF-1 could depend on a primitive defect of the axis, but also from malnutrition and hypermetabolic status of these patients [40]. In some cases, however, there is a real GHD due to a pituitary vascular insult during vaso-occlusive crises [41, 42]. These patients could benefit from a human recombinant GH replacement therapy [43]. Our data showed that mean values ​​of both IGF-1 and IGFBP-3 were lower in subjects with HbSS genotype compared to subjects with HbSC genotype and that IGF1-levels had a positive correlation with Hb and Hb mean values ​​of 2016 and a negative correlation with average LDH and LDH mean values ​​of 2016. These data underline how the clinical severity of the disease, the number of vaso-occlusive crises and chronic hemolysis could adversely affect GH-IGF-1-IGFBP-3 axis in SCD patients.

In our population 11.5% of patients had pathological HOMA index. In literature there is evidence of insulin resistance among patients with SCD [10]. A multicenter study by Fung et al. [44] revealed that for every 10 years of transfusion therapy, subjects with SCD have a 2.5 times greater probability to develop diabetes (while patients with thalassemia have a double risk). However, there are cases of insulin resistance in patients with normal oral glucose tolerance test. In these patients BMI values were above 85° percentile and none of the patients with normal weight had an insulin resistance condition [22]. However, it is important to point out that our study included a pediatric population with a normal BMI and this could also explain the reduced rate of diabetes. There is currently no agreement on the causes of this complication and further investigations are needed.

We found a case of hypergonadotropic hypogonadism and one case of ovarian failure in HbSS genotype group. The etiology of hypogonadism in SCD is not fully understood yet: in some cases, primitive gonadal failure is related to structural anomalies, resulting from chronic tissue damage associated with chronic anemia condition and local vaso-occlusive crises [45]. According to this hypothesis, our study demonstrated a direct correlation between Hb levels and testosterone average values in males, demonstrating how clinical control can affect reproductive function.

This study has some important limitations. This is a single center study with a small sample size. Secondly there are some confounders factors (i.e. genotype, gender…). The main outcome of this study was to report clinical features of our patients, in a cross sectional way, to better understand the actual prevalence of both metabolic alterations and endocrine complications. Surely, a longitudinal study design of these parameters will provide us more information on the natural history of these complications in SCD. However, it must be considered that in our country SCD is a rare disease and, at the best of our knowledge, this is the first Italian study on these topics. In literature there are very little data available on these condition in pediatric patients with SCD mainly in European Countries. We think that it is important to evaluate these conditions in different environmental setting.


Subjects with SCD show a high prevalence of metabolic alterations and endocrine complications. However, our results suggest that through the achievement of a good clinical control the SCD patients can obtain a positive impact on growth, metabolic and endocrine function.

Consequently, it is crucial to perform periodic anthropometric and endocrine evaluations, especially during puberty, and to have a comprehensive approach to this disease in order to reduce its long-term complications.



Acute Chest Syndrome


Italian Drugs Agency


Anti-mullerian hormone


Body Mass Index


Follicle-stimulating hormone


Free thyroxine 4


Growth Hormone






Homeostasis model assessment




Insulin-like Growth Factor-I


Insulin-like Growth Factor Binding Protein 3


Insulin resistance


Lactate dehydrogenase


Luteinizing hormone


Sickle Cell Disease


Standard Deviation Score


Target Height


Thyroid stimulating hormone


Vaso-occlusive crises


World Health Organization


  1. 1.

    Platt OS, Brambilla DJ, Rosse WF, Milner PF, Castro O, Steinberg MH, et al. Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med. 1994;330:1639–44.

    CAS  Article  Google Scholar 

  2. 2.

    Panepinto JA, O'Mahar KM, DeBaun MR, Loberiza FR, Scott JP. Health-related quality of life in children with sickle cell disease: child and parent perception. Br J Haematol. 2005;130:437–44.

    Article  Google Scholar 

  3. 3.

    Meier ER, Miller JL. Sickle cell disease in children. Drugs. 2012;72:895–906.

    CAS  PubMed  PubMed Central  Google Scholar 

  4. 4.

    Lodi M, Bigi E, Palazzi G, Vecchi L, Morandi R, Setti M, et al. Universal screening program in pregnant women and newborns at-risk for sickle cell disease: first report from northern Italy. Hemoglobin. 2017;41:230–3.

    CAS  Article  Google Scholar 

  5. 5.

    Quinn CT, Rogers ZR, McCavit TL, Buchanan GR. Improved survival of children and adolescents with sickle cell disease. Blood. 2010;115:3447–52.

    CAS  Article  Google Scholar 

  6. 6.

    Lobo CL, Ballas SK, Domingos AC, Moura PG, do Nascimento EM, Cardoso GP, et al. Newborn screening program for hemoglobinopathies in Rio de Janeiro, Brazil. Pediatr Blood Cancer. 2014;61:34–9.

    Article  Google Scholar 

  7. 7.

    Iughetti L, Bigi E, Venturelli D. Novel insights in the management of sickle cell disease in childhood. World J Clin Pediatr. 2016;5:25–34.

    Article  Google Scholar 

  8. 8.

    Barden EM, Kawchak DA, Ohene-Frempong K, Stallings VA, Zemel BS. Body composition in children with sickle cell disease. Am J Clin Nutr. 2002;76:218–25.

    CAS  Article  Google Scholar 

  9. 9.

    Rees DC, Williams TN, Gladwin MT. Sickle-cell disease. Lancet. 2010;376:2018–31.

    CAS  Article  Google Scholar 

  10. 10.

    Smiley D, Dagogo-Jack S, Umpierrez G. Therapy insight: metabolic and endocrine disorders in sickle cell disease. Nat Clin Pract Endocrinol Metab. 2008;4:102–9.

    CAS  Article  Google Scholar 

  11. 11.

    el-Hazmi MA, Bahakim HM, al-Fawaz I. Endocrine functions in sickle cell anaemia patients. J Trop Pediatr. 1992;38:307–13.

    CAS  Article  Google Scholar 

  12. 12.

    Hagag AA, El-Farargy MS, Elrefaey S, Abo El-enein AM. Study of gonadal hormones in Egyptian female children with sickle cell anemia in correlation with iron overload: single center study. Hematol Oncol Stem Cell Ther. 2016;9:1–7.

    CAS  Article  Google Scholar 

  13. 13.

    Hankins JS, Ware RE, Rogers ZR, Wynn LW, Lane PA, Scott JP, et al. Long-term hydroxyurea therapy for infants with sickle cell anemia: the HUSOFT extension study. Blood. 2005;106:2269–75.

    CAS  Article  Google Scholar 

  14. 14.

    World Health Organization Growth Reference. 2007. Accessed 7 Dec 2018.

  15. 15.

    Tanner JM, Goldstein H, Whitehouse RH. Standards for children’s height at ages 2–9 years allowing for height of parents. Arch Dis Child. 1970;47:755–62.

    Article  Google Scholar 

  16. 16.

    Marshall WA, Tanner JM. Variations in pattern of pubertal changes in girls. Arch Dis Child. 1969;44:291–3.

    CAS  Article  Google Scholar 

  17. 17.

    Keskin M, Kurtoglu S, Kendirci M, Atabek ME, Yazici C. Homeostasis model assessment is more reliable than the fasting glucose/insulin ratio and quantitative insulin sensitivity check index for assessing insulin resistance among obese children and adolescents. Pediatrics. 2005;115:500–3.

    Article  Google Scholar 

  18. 18.

    Kurtoğlu S, Hatipoğlu N, Mazıcıoğlu M, Kendirici M, Keskin M, Kondolot M. Insulin resistance in obese children and adolescents: HOMA-IR cut-off levels in the prepubertal and pubertal periods. J Clin Res Pediatr Endocrinol. 2010;2:100–6.

    Article  Google Scholar 

  19. 19.

    Iughetti L, Predieri B, Bruzzi P, Predieri F, Vellani G, Madeo SF, et al. Ten-year longitudinal study of thyroid function in children with Down's syndrome. Horm Res Paediatr. 2014;82:113–21.

    CAS  Article  Google Scholar 

  20. 20.

    Grimberg A, DiVall SA, Polychronakos C, Allen DB, Cohen LE, Quintos JB, et al. Drug and therapeutics committee and ethics Committee of the Pediatric Endocrine Society. Guidelines for growth hormone and insulin-like growth factor-I treatment in children and adolescents: growth hormone deficiency, idiopathic short stature, and primary insulin-like growth factor-1 deficiency. Horm Res Paediatr. 2016;86:361–97.

    CAS  Article  Google Scholar 

  21. 21.

    Brook C, Clayton P, Brown R. Brook's clinical pediatric endocrinology. 6th edition. Oxford: Wiley-Blackwell; 2009.

  22. 22.

    Özen S, Ünal S, Erçetin N, Taşdelen B. Frequency and risk factors of endocrine complications in Turkish children and adolescents with sickle cell Anemia. Turk J Hematol. 2013;30:25–31.

    Article  Google Scholar 

  23. 23.

    Al-Saqladi AW, Cipolotti R, Fijnvandraat K, Brabin BJ. Growth and nutritional status of children with homozygous sickle cell disease. Ann Trop Paediatr. 2008;28:165–89.

    Article  Google Scholar 

  24. 24.

    Zemel BS, Kawchak DA, Ohene-Frempong K, Schall JI, Stallings VA. Effects of delayed pubertal development, nutritional status, and disease severity on longitudinal patterns of growth failure in children with sickle cell disease. Pediatr Res. 2007;61:607–13.

    Article  Google Scholar 

  25. 25.

    Singhal A, Morris J, Thomas P, Dover G, Higgs D, Serjeant GR. Factors affecting prepubertal growth in homozygous sickle cell disease. Arch Dis Child. 1996;6:502–6.

    Article  Google Scholar 

  26. 26.

    Soliman A, el Zalabany M, Amer M, Ansari BM. Growth and pubertal development in transfusion-dependent children and adolescents with thalassaemia major and sickle cell disease: a comparative study. J Trop Pediatr. 1999;45:23–30.

    CAS  Article  Google Scholar 

  27. 27.

    Thomas PW, Singhal A, Hemmings-Kelly M, Serjeant GR. Height and weight reference curves for homozygous sickle cell disease. Arch Dis Child. 2000;82:204–8.

    CAS  Article  Google Scholar 

  28. 28.

    Buison AM, Kawchak DA, Schall J, Ohene-Frempong K, Stallings VA, Zemel BS. Low vitamin D status in children with sickle cell disease. J Pediatr. 2004;145:622–7.

    CAS  Article  Google Scholar 

  29. 29.

    Jackson TC, Krauss MJ, Debaun MR, Strunk RC, Arbelaez AM. Vitamin D deficiency and comorbidities in children with sickle cell anemia. Pediatr Hematol Oncol. 2012;29:261–6.

    CAS  Article  Google Scholar 

  30. 30.

    Garrido C, Cela E, Belendez C, Mata C, Huerta J. Status of vitamin D in children with sickle cell disease living in Madrid, Spain. Eur J Pediatr. 2012;171:1793–8.

    CAS  Article  Google Scholar 

  31. 31.

    Singhal A, Parker S, Linsell L, Serjeant G. Energy intake and resting metabolic rate in preschool Jamaican children with homozygous sickle cell disease. Am J Clin Nutr. 2002;75:1093–7.

    CAS  Article  Google Scholar 

  32. 32.

    Nolan VG, Nottage KA, Cole EW, Hankins JS, Gurney JG. Prevalence of vitamin D deficiency in sickle cell disease: a systematic review. PLoS One. 2015;10:e0119908.

    Article  Google Scholar 

  33. 33.

    Bell NH, Greene A, Epstein S, Oexmann MJ, Shaw S, Shary J. Evidence for alteration of the vitamin D-endocrine system in blacks. J Clin Invest. 1985;76:470–3.

    CAS  Article  Google Scholar 

  34. 34.

    O'Connor MY, Thoreson CK, Ramsey NL, Ricks M, Sumner AE. The uncertain significance of low vitamin D levels in African descent populations: a review of the bone and cardiometabolic literature. Prog Cardiovasc Dis. 2013;56:261–9.

    Article  Google Scholar 

  35. 35.

    Heaney RP. The importance of calcium intake for lifelong skeletal health. Calcif Tissue Int. 2002;70:70–3.

    CAS  Article  Google Scholar 

  36. 36.

    Gutierrez OM, Farwell WR, Kermah D, Taylor EN. Racial differences in the relationship between vitamin D, bone mineral density, and parathyroid hormone in the National Health and nutrition examination survey. Osteoporos Int. 2011;22:1745–53.

    CAS  Article  Google Scholar 

  37. 37.

    Seixas MO, Rocha LC, Carvalho MB, Menezes JF, Lyra IM, Nascimento VM, et al. Levels of high-density lipoprotein cholesterol (HDL-C) among children with steady-state sickle cell disease. Lipids Health Dis. 2010;9:91.

    Article  Google Scholar 

  38. 38.

    Luporini SM, Bendit I, Manhani R, Bracco OL, Manzella L, Giannella-Neto D. Growth hormone and insulin-like growth factor I axis and growth of children with different sickle cell anemia haplotypes. J Pediatr Hematol Oncol. 2001;23:357–63.

    CAS  Article  Google Scholar 

  39. 39.

    Collett-Solberg PF, Fleenor D, Schultz WH, Ware RE. Short stature in children with sickle cell anemia correlates with alterations in the IGF-I axis. J Pediatr Endocrinol Metab. 2007;20:211–8.

    CAS  Article  Google Scholar 

  40. 40.

    Mandese V, Marotti F, Bedetti L, Bigi E, Palazzi G, Iughetti L. Effects of nutritional intake on disease severity in children with sickle cell disease. Nutr J. 2016;15:46.

    Article  Google Scholar 

  41. 41.

    Soliman AT, Darwish A, Mohammed SH, Bassiony MR, el Banna N, Asfour M. Circulating growth hormone (GH), insulin-like growth factor-I (IGF-I) and free thyroxine, GH response to clonidine provocation and CT scanning of the hypothalamic-pituitary area in children with sickle cell disease. J Trop Pediatr. 1995;41:285–9.

    CAS  Article  Google Scholar 

  42. 42.

    Soliman AT, el Banna N, alSalmi I, De Silva V, Craig A, Asfour M. Growth hormone secretion and circulating insulin-like growth factor-I (IGF-I) and IGF binding protein-3 concentrations in children with sickle cell disease. Metabolism. 1997;46:1241–5.

    CAS  Article  Google Scholar 

  43. 43.

    Nunlee-Bland G, Rana SR, Houston-Yu PE, Odonkor W. Growth hormone deficiency in patients with sickle cell disease and growth failure. J Pediatr Endocrinol Metab. 2004;17:601–6.

    CAS  Article  Google Scholar 

  44. 44.

    Fung EB, Harmatz PR, Lee PD, Milet M, Bellevue R, Jeng MR, et al. Multi-Centre study of Iron overload research group. Increased prevalence of iron-overload associated endocrinopathy in thalassaemia versus sickle-cell disease. Br J Haematol. 2006;135:574–82.

    Article  Google Scholar 

  45. 45.

    Casale M, Ciliberti A, Colombatti R. Italian guidelines for the management of pediatric patients with sickle cell disease. Italian Ematology oncology pediatric association AIEOP 2012. Accessed 7 Dec 2018.

Download references


Not applicable


Not applicable

Availability of data and materials

The datasets generated and/or analysed during the current study are not publicly available due to privacy reason but are available from the corresponding author on reasonable request.

Author information




VM, EB and PB collected data. EB, VM, PB and LI conceived the study and its design, coordinated it and wrote the manuscript. PB performed the statistical analysis. GP, BP, MC, LL, and LI supervised and reviewed the manuscript making important intellectual contributions. All authors read and approved the final manuscript.

Corresponding author

Correspondence to L. Iughetti.

Ethics declarations

Ethics approval and consent to participate

Provincial Ethical Committee approved the protocol study (E.C. n. 213/16), informed consent was obtained for all enrolled patients. Parents and/or legal guardians provided the written informed consent for participation on behalf of the underage participants who were not of legal age to consent for themselves.

Consent for publication

Not applicable

Competing interests

Lorenzo Iughetti is an Editorial Board Member for BMC Pediatrics. All the others authors declared that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Additional file

Additional file 1:

Table S1. Anthropometric parameters in males and females. (DOCX 30 kb)

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (, which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Mandese, V., Bigi, E., Bruzzi, P. et al. Endocrine and metabolic complications in children and adolescents with Sickle Cell Disease: an Italian cohort study. BMC Pediatr 19, 56 (2019).

Download citation


  • Sickle cell disease
  • Metabolism
  • Endocrine complications
  • Children and adolescents